Penumbra (PEN) Net Cash Flow Growth (5y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.70% |
| Dec 31, 2025 | -68.57% |
| Sep 30, 2025 | -13.00% |
| Jun 30, 2025 | -6.62% |
| Mar 31, 2025 | 194.53% |
| Dec 31, 2024 | 25.96% |
| Sep 30, 2024 | -17.50% |
| Jun 30, 2024 | 40.78% |
| Mar 31, 2024 | 14.76% |
| Dec 31, 2023 | 26.74% |
| Sep 30, 2023 | -3.47% |
| Jun 30, 2023 | 19.78% |
| Mar 31, 2023 | 69.98% |
| Dec 31, 2022 | 25.04% |
| Sep 30, 2022 | 23.00% |
| Jun 30, 2022 | 19.93% |
| Mar 31, 2022 | -38.56% |
| Dec 31, 2021 | -15.78% |
| Sep 30, 2021 | -48.13% |
| Jun 30, 2021 | 66.07% |
| Mar 31, 2021 | -47.60% |
| Dec 31, 2020 | 41.17% |
| Sep 30, 2020 | -19.59% |
| Jun 30, 2020 | 16.90% |
| Mar 31, 2020 | -15.38% |
| Dec 31, 2019 | -54.59% |